About Efung Capital
Shenzhen Efung Capital, one of the earliest VC/PE companies in China, focuses on the investment of biopharmaceutical and medical device companies. Efung has invested about 20 new drug and medical device companies in China and internationally. Of which, Chipscreen (Shenzhen) marketed an anti-cancer new drug, Chidamide, in 2015; Frontier Biotech（Nanjing）will market Albuvirtide within months, which could become one of the world's first long-acting anti-HIV new drug ever approved; Ascentage Pharma (Jiangsu) and Gmax Biopharm (Hangzhou) will be IPO in NASDAQ in 2018. Since 2015, Efung initiated two U.S. Dollar Fundings and already invested 5 Pharmaceutical companies, such as Aridis, Reservlogix, Centrexion, et.al. We collaborate with many individual and institution investors, public listed pharmaceutical/medical device companies, investing banks and governmental agents from China, and internationally.
State of Ownership
Business Development Executive, Nature Publishing Group, Springer Nature